CITIUS ONCOLOGY INC
CTORNASDAQπ #4209 by market capEarnings Dec 21US Equity
$0.50βΌ $0.06 (β10.11%)
Market closed Β· at closeTrack CTOR
Get earnings, price moves & breaking news on Telegram
24hβΌ 10.1%
7dβΌ 9.7%
14dβΌ 5.1%
30dβΌ 4.8%
ytdβΌ 48.7%
1yβΌ 56.5%
π¦Market Cap
$47M
Small Cap
πRevenue Growth (YoY)
β
πGross Margin
β
π΅FCF Margin
β
βοΈP/S Ratio
β
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $0.50 β $0.54
- 52-Week Range
- $0.49 β $1.83
- Volume (shares)
- 3,500
- Avg Volume (shares)
- β
- Shares Outstanding
- 93.0M
- Next Earnings
- 2026-12-21
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $1M
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-0.48
- Dividend Yield
- β
- Dilution (1yr)
- +22.2%
CITIUS ONCOLOGY INC
CTORFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$24Mβ² +14.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$5MβΌ β4446.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
87.5Mβ² +22.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3Mβ² +$7M YoY
About CITIUS ONCOLOGY INC
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.